Liquidia Co. (NASDAQ:LQDA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Liquidia Co. (NASDAQ:LQDA) have received an average rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $24.67.

LQDA has been the subject of a number of recent analyst reports. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Scotiabank initiated coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Bank of America reduced their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Lifesci Capital began coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. Finally, HC Wainwright dropped their target price on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, August 20th.

Liquidia Stock Performance

Shares of LQDA opened at $10.98 on Monday. Liquidia has a fifty-two week low of $6.06 and a fifty-two week high of $16.99. The company has a market capitalization of $843.15 million, a price-to-earnings ratio of -6.99 and a beta of 0.21. The firm has a 50-day simple moving average of $10.30 and a 200-day simple moving average of $11.64.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. Equities research analysts forecast that Liquidia will post -1.69 EPS for the current year.

Insider Transactions at Liquidia

In other news, CEO Roger Jeffs sold 8,053 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the transaction, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at $9,023,464.23. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Liquidia news, Director Caligan Partners Lp acquired 150,000 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was acquired at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the purchase, the director now directly owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at $9,023,464.23. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,551 shares of company stock valued at $236,021 in the last ninety days. Corporate insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Patient Square Capital LP purchased a new stake in Liquidia in the 1st quarter worth approximately $105,942,000. Vanguard Group Inc. grew its stake in Liquidia by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after acquiring an additional 43,352 shares during the period. Farallon Capital Management LLC purchased a new stake in Liquidia in the 1st quarter worth approximately $30,311,000. Whitefort Capital Management LP grew its stake in Liquidia by 45.8% in the 1st quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock worth $4,980,000 after acquiring an additional 106,049 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock worth $3,396,000 after acquiring an additional 125,315 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).